“Dupilumab is a Predominant Treatment for Recalcitrant Bullous Pemphigoid”, ACCR, vol. 4, no. 1, pp. 1–4, Feb. 2021, Accessed: Sep. 14, 2026. [Online]. Available: https://somatopub.com/index.php/ACCR/article/view/17